Irina Y Shalaurova

This inventor holds 21 USPTO granted patents and 4 published patent applications, plus 7 CIPO patents and 6 EPO patents, primarily in Cardiovascular Risk Assessment. Top assignees: Liposcience, Inc., Liposciences, LLC, Other. Active years: 2003-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Irina Y Shalaurova. Retrieved from https://idiyas.com/inventor/irina-y-shalaurova

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 4)

% Patents Active = 95.2

CIPO Patents = 7 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 82(Granted Patents)

Company Filing History:

2 out of 834,659

Other

patents

Years Active: 2003-2024

Loading Chart...

Areas of Expertise:

NMR Spectroscopy

Metabolic Vulnerability

Diabetes Risk

Cardiovascular Risk

Lipoprotein X

HDL Biomarkers

GlycA Measurement

Multiple-Marker Parameters

CHD Stratification

Inflammatory Biomarkers

HDL-P Levels

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12130295 - NMR system and methods for multi-parameter metabolic vulnerability index evaluations (2024-10-29),

2. 11990243 - Multiple-marker risk parameters predictive of conversion to diabetes (2024-05-21),

3. 11988679 - Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter (2024-05-21),

4. 11710568 - Multi-parameter diabetes risk evaluations (2023-07-25),

5. 11703501 - CHD risk stratification evaluations for subjects with high levels of large HDL-P (2023-07-18),

6. 11692995 - NMR measurements of NMR biomarker GlycA (2023-07-04),

7. 11467171 - Methods and systems to detect and quantify the amount of LP-X and other abnormal lipoproteins in a biosample using NMR spectroscopy (2022-10-11),

8. 11231429 - Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter (2022-01-25),

9. 11156621 - Multi-parameter metabolic vulnerability index evaluations (2021-10-26),

10. 11037683 - Multiple-marker risk parameters predictive of conversion to diabetes (2021-06-15),

11. 10852293 - NMR measurements of NMR biomarker GlycA (2020-12-01),

12. 10388414 - Multi-parameter diabetes risk evaluations (2019-08-20),

13. 10386355 - CHD risk stratification evaluations for subjects with high levels of large HDL-P (2019-08-20),

14. 9952232 - Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter (2018-04-24),

15. 9928345 - Multiple-marker risk parameters predictive of conversion to diabetes (2018-03-27),

Title: The Innovative Contributions of Irina Y Shalaurova

Introduction

Irina Y Shalaurova, located in Cary, NC, is a prominent inventor recognized for her significant contributions to the field of metabolic research, holding an impressive total of 21 patents. Her work primarily focuses on evaluating health risks through innovative methods and systems linked to metabolic vulnerability and diabetes.

Latest Patents

Among her latest inventions is the NMR system and methods for multi-parameter metabolic vulnerability index evaluations. This patent reveals methodologies to assess a subject's metabolic vulnerability index (MVX) score by utilizing mathematically defined risk models. The system evaluates several biomarkers to identify various health risks, including a relative risk of premature all-cause mortality. Additionally, she has developed methods pertaining to multiple-marker risk parameters predictive of conversion to diabetes. This innovative approach employs defined mathematical models to evaluate a subject's risk of developing type 2 diabetes, particularly assisting in stratifying risks for patients with similar glucose measurements.

Career Highlights

Irina has made notable strides in her career, working with reputable organizations such as Liposcience, Inc. Her professional journey showcases her dedication to advancing healthcare diagnostics through inventiveness and problem-solving in the realm of metabolic health.

Collaborations

Throughout her career, Irina has collaborated with esteemed colleagues, including James D. Otvos and Dennis W. Bennett. These partnerships highlight a shared commitment to innovation and excellence in medical research, further amplifying the impact of her contributions.

Conclusion

Irina Y Shalaurova's contributions to innovations in metabolic research reveal her exceptional capabilities as an inventor. Through her numerous patents and collaborative efforts, she has significantly advanced methodologies that assess health risks, particularly concerning metabolic vulnerability and diabetes. Her work stands as a testament to the power of innovation in improving health outcomes.

Profile summary based on public USPTO records.